IDT Biologika and Oncotec Pharma Produktion Announce Expansion Projects - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

IDT Biologika and Oncotec Pharma Produktion Announce Expansion Projects



IDT Biologika GmbH, a developer of pharmaceutical technology and a producer of proprietary and third-party biopharmaceuticals and viral and bacterial vaccines, and Oncotec Pharma Produktion have reported investments to increase their production capacities. IDT will invest €40 million ($55 million) in its vaccine and parenteral sterile fill-and-finish capacities in syringes, vials, lyophilization, and packaging at its BioPharmaPark, located in Dessau-Roβlau, Germany. Among the upgrades are serialization and anti-counterfeiting capabilities designed to enable the authentication of finished pharmaceuticals.

In September 2013, IDT started up its new production capacity for sterile parenteral drug products, including vaccines and biologics, having completed an expansion project announced in 2011. Capacity to manufacture vial-based products in liquid and lyophilized form will increase to 60 million units per year. Oncotec Pharma Produktion GmbH, a pharmaceutical manufacturing partner of aseptically produced cytostatic drug products, will invest €30 million ($41 million) to expand sterile parenteral oncology drug manufacturing capacity within IDT’s BioPharmaPark. Manufacturing facilities and pharmaceutical site infrastructure will be enlarged over the next few years. The expansion projects are expected to be complete in 2016.

Source: IDT Biologika

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
30%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
8%
All of the above.
45%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics

Click here